ExodusPoint Capital Management’s Soleno Therapeutics SLNO Stock Holding History

ExodusPoint Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,240	Closed	-$778K	–	2019
2026 Q1	$778K	Buy	+23,240	New	+$911K	0.01%	1064
2024 Q2	–	Sell	-14,206	Closed	-$608K	–	1944
2024 Q1	$608K	Buy	+14,206	New	+$643K	﹤0.01%	1094
2021 Q3	–	Sell	-734	Closed	-$13K	–	2585
2021 Q2	$13K	Sell	734 -52	-7%	-$879	﹤0.01%	2261
2021 Q1	$15K	Buy	+786	New	+$25.3K	﹤0.01%	2058
2020 Q2	–	Sell	-1,476	Closed	-$53K	–	2004
2020 Q1	$53K	Buy	+1,476	New	+$62.8K	﹤0.01%	956

ExodusPoint Capital Management's SLNO Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 23,240 shares — an estimated $778K sold.

ExodusPoint Capital Management first reported a position in SLNO in Q1 2020 and held it in 5 quarters. The position peaked at $778K in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

ExodusPoint Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 23,240 Soleno Therapeutics shares in Q2 2026, an estimated $778K.
ExodusPoint Capital Management first reported a position in Soleno Therapeutics in Q1 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Soleno Therapeutics position peaked at $778K in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.